April 26/27, 2012 - Asahi Kasei Completes Acquisition of ZOLL Asahi Kasei Completes Acquisition of ZOLL Tokyo, Japan/ New York, NY, U.S. – April 27/26, 2012 – Asahi Kasei Corporation (TSE1: 3407, hereinafter: Asahi Kasei), Japan’s leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, announced today the successful completion of its acquisition of ZOLL Medical Corporation (hereinafter: ZOLL), a major US manufacturer of medical devices for critical care, on April 26, 2012, US Eastern time. On March 12, 2012, Asahi Kasei announced a tender offer for shares of ZOLL, through a US subsidiary. All procedures related to this acquisition were completed on April 26, 2012, US Eastern time, and ZOLL became a wholly owned consolidated subsidiary of Asahi Kasei. As a result, ZOLL’s stock will cease to be traded on the NASDAQ market, and ZOLL will no longer have reporting obligations under the Securities Exchange Act of 1934. ZOLL will continue to be managed by its current management team. MEDIA CONTACTS Asahi Kasei Corporation: Corporate Communications: Tokyo +81-3-3296-3008 (M. Nakamura)Kreab Gavin Anderson: Tokyo +81-3-5404-0640 (M. Hattori, D. Stawinoga) New York +1-646-490-2767 (J. Goldman-Brown) About Asahi Kasei Corporation Asahi Kasei is Japan’s leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors. The company’s growth strategy involves continuous transformation of its business portfolio through constant innovation in anticipation of emerging changes to market needs, and through this process Asahi Kasei has developed into a diversified solution provider. With more than 25,000 employees around the world, the company serves customers in more than 100 countries. Within the health care field, the company is active in pharmaceuticals (including agents for dysuria, osteoporosis, disseminated intravascular coagulation, and herpes), medical devices (including artificial kidneys and therapeutic apheresis devices), and bioprocess products (including virus removal filters and bioprocess equipment). For more information, visit www.asahi-kasei.co.jp/asahi/en/. About ZOLL Medical Corporation ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care. A three-time Forbes 100 Most Trustworthy Company, ZOLL was designated in 2011 as one of Forbes Top 100 Small Public Companies in America with annual revenues under $1 billion. ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.